CompletedPhase 3NCT00003325
Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
Studying Vulvar carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Charles Levenback, MDM.D. Anderson Cancer Center
- Intervention
- Sentinel lymph node mapping(procedure)
- Enrollment
- 515 enrolled
- Eligibility
- FEMALE
- Timeline
- 1999
Study locations (30)
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Todd Cancer Institute at Long Beach Memorial Medical Center, Long Beach, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Helen and Harry Gray Cancer Center at Hartford Hospital, Hartford, Connecticut, United States
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
- George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus, New Britain, Connecticut, United States
- Washington Cancer Institute at Washington Hospital Center, Washington D.C., District of Columbia, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States
- Hinsdale Hematology Oncology Associates, Hinsdale, Illinois, United States
- Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States
- Elkhart General Hospital, Elkhart, Indiana, United States
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- Gynecologic Oncology of Indiana, Indianapolis, Indiana, United States
- St. Vincent Indianapolis Hospital, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003325 on ClinicalTrials.govOther trials for Vulvar carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06447064Cancer Loyalty Card Study 2 (CLOCS-2)Imperial College London
- RECRUITINGNCT07380698The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological CancerCukurova University
- ENROLLING BY INVITATIONNANCT07023601International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.Hospital Universitario La Paz
- RECRUITINGPHASE2NCT05903833Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or RadiotherapyAGO Research GmbH
- RECRUITINGNANCT05576831STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide ExcisionBritish Columbia Cancer Agency
- RECRUITINGNANCT06495554Danish Vulva Cancer Recurrence StudyUniversity of Aarhus
- RECRUITINGNANCT06264167NODE (groiN ultrasOunD cancEr)Queensland Centre for Gynaecological Cancer
- ACTIVE NOT RECRUITINGNANCT06694116Charcoal Carbon Black Dye Use in Sentinel Lymph Node Mapping in Early Stage Vulvar CancerIstanbul University